AI Engines For more Details: Perplexity Kagi Labs You
Muscle Relaxation: Decamethonium bromide acts as a depolarizing neuromuscular blocking agent, causing temporary paralysis of skeletal muscles by binding to nicotinic acetylcholine receptors at the neuromuscular junction. This results in muscle relaxation, which is essential for achieving optimal surgical conditions and facilitating procedures such as endotracheal intubation.
Anesthesia: Decamethonium bromide is commonly administered as part of anesthesia induction to facilitate rapid onset of muscle relaxation and tracheal intubation. By paralyzing skeletal muscles, decamethonium bromide allows for easier insertion of the endotracheal tube and helps prevent movement and reflex responses during surgery.
Endotracheal Intubation: Endotracheal intubation is a procedure performed to establish and maintain a patent airway in individuals undergoing general anesthesia or requiring mechanical ventilation. Decamethonium bromide facilitates endotracheal intubation by inducing muscle relaxation, which reduces the risk of airway obstruction and facilitates insertion of the endotracheal tube into the trachea.
Surgical Procedures: Decamethonium bromide is used in a wide range of surgical procedures, including abdominal surgery, orthopedic surgery, cardiovascular surgery, and emergency surgery. It helps achieve optimal muscle relaxation, allowing surgeons to perform procedures more effectively and safely.
Rapid Onset and Short Duration: One of the advantages of decamethonium bromide is its rapid onset of action, typically within 30 to 60 seconds after administration. This rapid onset allows for quick induction of muscle relaxation, making it particularly useful in emergency situations or when immediate airway control is required. However, its duration of action is relatively short, usually lasting several minutes, requiring careful titration and monitoring during anesthesia.
Contraindications: Decamethonium bromide is contraindicated in individuals with a history of malignant hyperthermia, a rare but potentially life-threatening reaction to certain anesthetic agents. It should also be used with caution in individuals with neuromuscular disorders such as myasthenia gravis or Eaton-Lambert syndrome, as well as in individuals with severe cardiovascular disease or electrolyte imbalances.
Side Effects and Complications: Common side effects of decamethonium bromide may include bradycardia (slow heart rate), hypotension (low blood pressure), increased intraocular pressure, and fasciculations (muscle twitching). Rare but serious complications may include hyperkalemia (elevated blood potassium levels), malignant hyperthermia, prolonged paralysis, and allergic reactions.
Monitoring and Management: During administration of decamethonium bromide, vital signs such as heart rate, blood pressure, and oxygen saturation should be closely monitored. In addition, neuromuscular monitoring techniques such as train-of-four (TOF) stimulation may be used to assess the depth of neuromuscular blockade and guide dosing adjustments.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 0.6 | 0.6 | 0 |
| Allergies | 0.6 | 0.4 | 0.5 |
| Allergy to milk products | 0.6 | 0.6 | |
| Alzheimer's disease | 0.6 | 1.1 | -0.83 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | 0 |
| Ankylosing spondylitis | 0.3 | -0.3 | |
| Anorexia Nervosa | 0.3 | 0.6 | -1 |
| Antiphospholipid syndrome (APS) | 0.3 | -0.3 | |
| Asthma | 0 | 0 | |
| Atherosclerosis | 0.3 | 0.3 | |
| Atrial fibrillation | 0.9 | 0.4 | 1.25 |
| Autism | 1.1 | 1.1 | 0 |
| Bipolar Disorder | 0.9 | 0.9 | 0 |
| Brain Trauma | 0.3 | -0.3 | |
| Cancer (General) | 0.2 | -0.2 | |
| Carcinoma | 0.9 | 0.3 | 2 |
| Celiac Disease | 0.1 | 0.6 | -5 |
| Cerebral Palsy | 0.3 | -0.3 | |
| Chronic Fatigue Syndrome | 0.9 | 1.5 | -0.67 |
| Chronic Kidney Disease | 0.3 | 0.6 | -1 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.3 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.3 | -0.3 | |
| Cognitive Function | 0.3 | 0.3 | |
| Colorectal Cancer | 0.7 | 0.6 | 0.17 |
| Constipation | 0.4 | 0.4 | |
| Coronary artery disease | 0.6 | 0.4 | 0.5 |
| COVID-19 | 0.8 | 1.5 | -0.88 |
| Crohn's Disease | 1.3 | 0.7 | 0.86 |
| Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
| deep vein thrombosis | 0.3 | 0.3 | 0 |
| Depression | 1.7 | 1.7 | 0 |
| Endometriosis | 0.3 | 0.6 | -1 |
| Fibromyalgia | 0.3 | 0.6 | -1 |
| Functional constipation / chronic idiopathic constipation | 0.7 | 0.6 | 0.17 |
| gallstone disease (gsd) | 0.3 | 0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.1 | |
| Generalized anxiety disorder | 0.6 | 0.3 | 1 |
| Gout | 0.3 | 0.3 | 0 |
| Graves' disease | 0.3 | 0.6 | -1 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.3 | 0.3 | 0 |
| Heart Failure | 0.6 | 0.4 | 0.5 |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.3 | -0.3 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.3 | 0.9 | -2 |
| Hypothyroidism | 0.6 | -0.6 | |
| IgA nephropathy (IgAN) | 0.6 | 0.6 | |
| Inflammatory Bowel Disease | 0.5 | 1.2 | -1.4 |
| Insomnia | 0.3 | 0.6 | -1 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | 0.3 | 0 |
| Irritable Bowel Syndrome | 0.3 | 0.7 | -1.33 |
| ischemic stroke | 0.3 | 0.3 | 0 |
| Liver Cirrhosis | 1.5 | 0.9 | 0.67 |
| Long COVID | 1.4 | 1.3 | 0.08 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.3 | 0.3 | 0 |
| Mast Cell Issues / mastitis | 0.6 | -0.6 | |
| ME/CFS with IBS | 0.1 | 0.6 | -5 |
| ME/CFS without IBS | 0.3 | 0.3 | |
| Metabolic Syndrome | 1.3 | 1 | 0.3 |
| Mood Disorders | 1.5 | 2 | -0.33 |
| Multiple Sclerosis | 1.1 | 0.7 | 0.57 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| neuropathic pain | 0.3 | 0.3 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 0.7 | -1.33 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | |
| Obesity | 0.9 | 1.1 | -0.22 |
| obsessive-compulsive disorder | 0.3 | 0.6 | -1 |
| Osteoarthritis | 0.3 | -0.3 | |
| Osteoporosis | 0.6 | 0.6 | |
| Parkinson's Disease | 1 | 0.9 | 0.11 |
| Polycystic ovary syndrome | 0.9 | 0.7 | 0.29 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.6 | -0.6 | |
| Psoriasis | 0.3 | 0.4 | -0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.3 | 0.4 | 2.25 |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 1.2 | 0.6 | 1 |
| scoliosis | 0.3 | 0.6 | -1 |
| Sjögren syndrome | 0.3 | -0.3 | |
| Sleep Apnea | 0.6 | 0.9 | -0.5 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.3 | -0.3 | |
| Systemic Lupus Erythematosus | 0.9 | 0.3 | 2 |
| Tic Disorder | 0.4 | 0.4 | |
| Type 1 Diabetes | 1 | 0.4 | 1.5 |
| Type 2 Diabetes | 2 | 0.7 | 1.86 |
| Ulcerative colitis | 0.2 | 1 | -4 |
| Unhealthy Ageing | 1.1 | 0.4 | 1.75 |
| Vitiligo | 0.3 | 0.6 | -1 |
